Urovant launches US$150m IPO
Swiss biopharma company Urovant Sciences has launched its IPO on Nasdaq, seeking US$150m. The proceeds will go to Phase III trials for its overactive bladder treatment candidate vibegron.
Author Archive for: UM
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 42 entries already.
Entries by Uta Mommert
Immunooncology: Genmab teams up with Immatics
/in News/by Uta MommertDanish Genmab and German Immatics Biotechnologies are collaborating to discover and develop next-generation bispecific immunotherapies to develop therapeutics in multiple cancer indications.